CRISPR Therapeutics to Present at Morgan Stanley Healthcare Conference
Event summary
- CRISPR Therapeutics will present at the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, 2026, at 1:05 p.m. EST.
- A live webcast of the fireside chat will be available on the company's website, with a replay archived for 14 days.
- CRISPR Therapeutics is a leading biopharmaceutical company focused on CRISPR/Cas9 gene editing, with the approval of CASGEVY® for sickle cell disease and beta thalassemia.
- The company is advancing a diversified pipeline spanning multiple therapeutic areas and has strategic collaborations, including with Vertex Pharmaceuticals.
The big picture
CRISPR Therapeutics' presentation at the Morgan Stanley conference comes at a pivotal time for the gene editing sector, as the company seeks to capitalize on the approval of its first CRISPR-based therapy. The strategic collaborations and diversified pipeline position CRISPR Therapeutics as a key player in the biopharmaceutical industry, with significant potential for growth and innovation.
What we're watching
- Pipeline Progress
- How CRISPR Therapeutics' diversified pipeline will impact its market position and revenue growth.
- Strategic Collaborations
- Whether the partnership with Vertex Pharmaceuticals will accelerate the development of new therapies.
- Market Expansion
- The pace at which CRISPR Therapeutics can expand its gene editing toolkit through SyNTase™ editing.
Related topics